Restoring Ranbaxy: Critical for India’s success in global generics exports

When Daiichi Sankyo acquired Ranbaxy Laboratories from the Singh brothers in June, 2008, the pharmaceuticals major would not have imagined it would be in for so much trouble. The Japanese firm bought a controlling interest in Ranbaxy at a market capitalisation of close to R21,000 crore; since then the stock has lost about a third of its value, with the market cap at around R14,000 crore.

Read Full Story>>